PMID: 6967859Jan 1, 1980Paper

Use of H-2 mutations to quantitate alloreactivity: Alloreactivity is strongest against H-2 antigens which are closet to self

Immunogenetics
M Pimsler, J Forman

Abstract

Lymph-node cells from H-2 allogeneic, intra-H-2 recombinant and H-2 mutant congenic strains were sensitized in limiting dilution cultures to quantitate the cytotoxic T-lymphocyte precursor frequencies (CTL.Pf) against antigens encoded by different regions of the H-2 complex. When four H-2Kb mutants of C57BL/6 (B6) were tested, we observed anti-B6 CTL.Pf that were as high or higher than those of recombinant strains which differ from B6 at the K end of the H-2 complex. Relative to strains completely H-2 allogeneic to B6, the CTL.Pf in H-2bm3 and H-2bm5 averaged 40--50 percent, and H-2bm8 averaged 140 percent. Recombinant strains B10.A (4R) and B10.D2 (R103), which differ from B6 at the K end of the H-2 complex, averaged 60 percent of the completely H-2 allogeneic value. Since the mutant and wild-type gene products have no serological and minimal structural differences relative to other alleles at H-2K, these results indicate that the CTL.Pf does not increase with increasing H-2 antigenic disparity between andy two strains. Rather, the data suggests that the T-cell receptor repertoire recognizes those H-2 molecules or determinants closest to self.

References

Jan 1, 1977·Immunological Reviews·I F McKenzieR V Blanden
Jan 1, 1979·Immunological Reviews·J W Streilein
Sep 1, 1978·The Journal of Experimental Medicine·F H Bach, B J Alter
May 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·M J Bevan
Jan 1, 1977·Immunological Reviews·F H BachM L Bach
Oct 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·R FinbergB Benacerraf
Jan 1, 1977·Cold Spring Harbor Symposia on Quantitative Biology·S G NathensonJ H Freed
Mar 1, 1977·Proceedings of the National Academy of Sciences of the United States of America
Jan 1, 1977·Cold Spring Harbor Symposia on Quantitative Biology·H Cantor, E A Boyse
Sep 19, 1979·The Journal of Experimental Medicine·R M ZinkernagelG Callahan
Jan 1, 1977·Immunological Reviews·R G MillerR A Phillips
Jun 1, 1976·The Journal of Experimental Medicine·M A Skinner, J Marbrook
May 1, 1973·The Journal of Experimental Medicine·B J AlterJ H Stimpfling
Nov 1, 1968·The Journal of Experimental Medicine·D B Wilson, P C Blyth JL NOWELL
Dec 1, 1978·Immunogenetics·H I KohnD C Shreffler

❮ Previous
Next ❯

Citations

Aug 12, 2003·Trends in Immunology·Dominique Housset, Bernard Malissen
Mar 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·M J Bevan, T Hünig
Feb 1, 1982·European Journal of Immunology·J Langhorne, K F Lindahl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.